Phase IV Multicenter Open Label Randomized Study of Rebif 44mcg Administered Three Times Per Week by Subcutaneous Injection Compared With no Treatment in the Therapy of Relapsing Multiple Sclerosis After Mitoxantrone.

Trial Profile

Phase IV Multicenter Open Label Randomized Study of Rebif 44mcg Administered Three Times Per Week by Subcutaneous Injection Compared With no Treatment in the Therapy of Relapsing Multiple Sclerosis After Mitoxantrone.

Completed
Phase of Trial: Phase IV

Latest Information Update: 26 Apr 2014

At a glance

  • Drugs Interferon beta-1a (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Acronyms REMAIN
  • Sponsors EMD Serono; Merck Serono
  • Most Recent Events

    • 15 Jan 2011 Actual end date (Jan 2010) added as reported by ClinicalTrials.gov.
    • 15 Jan 2011 Actual end date (Jan 2010) added as reported by ClinicalTrials.gov.
    • 15 Jan 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top